A cohort study presented at the AUA 2026 press program in Washington this week links finasteride 1mg - the hair loss dose - to new-onset erectile dysfunction at three years in a propensity-matched cohort of over 10,000 young men. This is the longest follow-up signal we’ve seen for this question, and it lands while the MHRA’s strengthened psychiatric and sexual side effect warnings are still fresh.
Worth taking seriously, even before peer review.
Why This Study Stands Out
The finasteride-ED question has been argued in circles for years. The trial data the drug was licensed on showed short-term sexual side effects that mostly resolved on stopping. The post-marketing reports and patient-led “post-finasteride syndrome” advocacy pointed to persistent effects. The literature in between has been mixed: small studies, short follow-up, confounding by indication, and selection bias in who gets reported.
This study addresses several of those weaknesses at once.
Sample size. Over 10,000 young men. Big enough to detect modest effect sizes and to do meaningful subgroup analysis.
Propensity matching. This is the methodological core. By matching finasteride users to non-users on baseline characteristics - age, comorbidities, baseline sexual function indicators, mental health history, other medications - the design reduces the confounding that has plagued earlier observational studies. It’s not as clean as randomisation, but it’s the best non-randomised tool we have for this kind of question.
Three-year follow-up. Most prior data only covered months, not years. A signal that holds at three years is fundamentally different from a transient effect that fades. It suggests the drug is doing something durable to androgen signalling or downstream pathways that doesn’t reset when you stop.
What We Don’t Know Yet
This is a press program presentation, not a peer-reviewed publication. The headlines need a wait-for-the-paper caveat.
We don’t have the effect size in absolute terms. Relative risk and hazard ratios need denominators to translate into clinic numbers. “A 25-year-old man on finasteride has a 1.5x risk of ED at three years compared to a matched non-user” sounds very different to “an additional 8 per 1000 will develop ED that they wouldn’t otherwise have had.” Both could be true at the same time. The conversation with a patient needs the second number.
We don’t know about persistence after stopping. The MHRA position is that sexual side effects may persist after discontinuation. The post-finasteride syndrome literature claims this strongly. A 3-year follow-up of current users doesn’t directly answer the durability-after-stopping question.
We don’t know the mechanism. Finasteride is a 5-alpha reductase inhibitor that blocks the conversion of testosterone to DHT. It also affects neurosteroids - allopregnanolone, in particular - which has been the mechanistic hypothesis for both the mood and sexual effects. But mechanism isn’t fully nailed down, and that matters for predicting who’s at risk.
Where This Fits With Last Week’s MHRA Update
The MHRA’s 11 May 2026 drug safety update strengthened the psychiatric and sexual side effect warnings for finasteride and dutasteride. For finasteride 1mg specifically, the SmPC is being updated to warn that sexual dysfunction may contribute to mood disorders, and that sexual dysfunction has also been reported without mood alterations.
That update was based on European referral data, Yellow Card reports, and a literature review with “mixed outcomes.” This new AUA 2026 cohort doesn’t change the regulatory advice, but it strengthens the empirical foundation underneath it. The regulatory caution was a reasonable position based on signal. This study moves it closer to a probable effect with measurable magnitude.
The combined picture for finasteride 1mg in young men is now:
- A regulator that has explicitly linked sexual dysfunction to mood disorders
- A 10,000+ patient cohort showing new-onset ED at 3 years
- Patient cards in every pack since 2024
- Persistent effects flagged in product information
- And an indication that is, for the vast majority of users, cosmetic
That’s a different risk-benefit conversation than it was even 18 months ago.
What Changes in Clinic
Probably nothing if you’re prescribing dutasteride for a 70-year-old in retention. The indication is medical, the alternatives are limited, and the benefit-harm calculus favours treatment.
It changes the conversation for finasteride 1mg in young men, especially private patients seeking treatment for androgenetic alopecia. The honest consent should now include:
The drug works for hair loss. It also affects androgen signalling system-wide.
Sexual side effects can develop during treatment and may persist after stopping. This is now a regulator-acknowledged risk, not a fringe claim.
A 3-year follow-up cohort suggests new-onset ED is a measurable risk, even with appropriate baseline matching.
Mood effects are formally linked to the sexual side effects, not just listed as separate adverse events.
The MHRA position is to stop immediately if depression or suicidal thoughts develop on finasteride 1mg.
Patient cards exist for a reason. Hand them over and actually talk through them.
This isn’t paternalistic gatekeeping. It’s giving young men the information they need to make a properly informed elective decision about a system-wide hormonal modulator.
AUA 2026 Press Program, May 2026. Propensity-matched cohort of finasteride 1mg users, 3-year follow-up (n>10,000).
MHRA Drug Safety Update, 11 May 2026: Finasteride and Dutasteride - updated safety warnings for psychiatric side effects and sexual dysfunction. gov.uk/drug-safety-update.